LIFECORE BIOMEDICAL, INC. Finance Lease, Weighted Average Discount Rate, Percent
LIFECORE BIOMEDICAL, INC. (LFCR) had Finance Lease, Weighted Average Discount Rate, Percent of 8.91% as of 2025-02-23, per its 10-Q filed 2025-04-03.
Financial Statements › Notes › Leases
us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent · last filed 2025-04-03
- 2025-02-23: Finance Lease, Weighted Average Discount Rate, Percent 8.91%.
- 2024-05-26: Finance Lease, Weighted Average Discount Rate, Percent 11.10%.
- 2024-02-25: Finance Lease, Weighted Average Discount Rate, Percent 11.10%.
- 2023-05-28: Finance Lease, Weighted Average Discount Rate, Percent 11.40%.
| Period end | Finance Lease, Weighted Average Discount Rate, Percent | Finance Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2025-02-23 | 8.91% 10-Q · filed 2025-04-03 | |
| 2024-05-26 | 11.10% 10-K · filed 2024-08-26 | |
| 2024-02-25 | 11.10% 10-Q · filed 2025-04-03 | |
| 2023-05-28 | 11.40% 10-K · filed 2024-08-26 | |
| 2022-05-29 | 10.01% 10-K · filed 2024-03-20 | 10.00% 10-K · filed 2022-09-14 |
| 2021-05-30 | 10.00% 10-K/A · filed 2023-03-16 | 1000.00% 10-K · filed 2021-07-29 |
| 2020-05-31 | 10.00% 10-K · filed 2021-07-29 | 1000.00% 10-K · filed 2020-08-14 |
| 2020-02-23 | 9.99% 10-Q · filed 2020-04-03 | |
| 2019-11-24 | 9.99% 10-Q · filed 2020-01-02 | |
| 2019-08-25 | 9.99% 10-Q · filed 2019-10-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |